GlassScriptPhysician profile
Kristine E Gould
NPI 1801839303
$7,441.74
in general payments reported to CMS, 2019-2025
42 companies · $686 in 2025
The $686 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $1,126 · 2021: $1,430 · 2022: $1,423 · 2023: $1,343 · 2024: $842 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,785 · Education: $85.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,785.04 |
| Education | $85.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,201.87 | 2019-2025 | |
| Novo Nordisk INC | $954.73 | 2020-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $462.38 | 2019-2025 | |
| Astellas Pharma US INC | $443.53 | 2019-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $364.99 | 2021-2025 | |
| Lumenis Be INC | $340.23 | 2021-2022 | |
| Exeltis, USA INC. | $292.60 | 2019-2025 | Slynd |
| Allergan, INC. | $264.84 | 2019-2022 | |
| Evofem Biosciences, INC. | $237.82 | 2020-2025 | Phexxi, Solosec, Phexx |
| Lupin INC. | $225.08 | 2019-2021 | |
| Therapeuticsmd, INC. | $219.91 | 2019-2022 | |
| Revance Therapeutics, INC. | $197.12 | 2024-2025 | Daxxify |
| Myovant Sciences INC. | $181.23 | 2021-2022 | |
| Millicent US INC | $172.98 | 2020-2025 | Intrarosa, Femlyv, Femring |
| Organon LLC | $146.83 | 2021-2025 | Nexplanon |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristine Gould listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.